Why drug development is hard #34 — designer hallucinogens

NBOMe (2-(4-Bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl]ethanamine to you) is a potent hallucinogen, a member of the phenylethylamine series of hallucinogens.  Well that’s the same as saying the current Intel chips are a member of the Intel class of starting with the 8080. https://psychonautwiki.org/wiki/25B-NBOMe has the structure, but I count 2 methoxy groups and a bromine on the phenyl group and a methoxy benzyl group making the amine group a secondary amine.

How anyone came up with the structure will remain unknown to me as it was part of a PhD thesis written in 2003 — unfortunately in German —Ralf Heim (February 28, 2010). “Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts.” (in German). diss.fu-berlin.de. Retrieved 2013-05-10.

Like other hallucinogens (LSD, mescaline, psilocin) NBOMe binds to the 2A variety of serotonin receptor (aka 5HT2A — at least 16 serotonin receptors are known) and acts like LSD as an agonist.

Which brings me to Cell vol. 182 pp. 1574 – 1588 ’20 — https://www.cell.com/cell/fulltext/S0092-8674(20)31066-7, probably behind a paywall.  Which has beautiful cryoEM structures of 5HT2A bound to LSD, NBOMe and methiothepin, an inverse agonist.  To get pictures they had to stabilize the structure with a single chain variable fragment of an antibody (something that always makes me wonder how physiologic the structure obtained actually is).

Why use NBOMe as an example of how hard drug discovery is?  Well the binding site of LSD to 5HT2A is well known, and the paper has some beautiful pictures of LSD snuggled between the 7 transmembrane segments of 5HT2A.  What is remarkable about NBOMe is that it lies in the binding site in a completely different orientation.  Moreover NBOMe fits in a previously undescribed pocket between transmembrane segments #3 and #6 (TM3, TM6).  Actually I think NBOMe actually produces the pocket.

So even if you know the target of your drug (5HT2A) and how another drug hits the target you’re aiming for, this doesn’t help you in designing a newer and more potent drug.

Post a comment or leave a trackback: Trackback URL.

Comments

  • Mark Thorson  On September 29, 2020 at 11:46 am

    Imodium is the only opioid you can buy OTC (unless Narcan is now OTC) because it’s such an efficient P-glycoprotein substrate that it doesn’t make it past the intestinal wall. Naloxone is such a powerful opioid antagonist that it can bring someone out of an OD within minutes. Does it seem likely you could combine whatever makes these opioids special in the same molecule to make a drug that would counteract the constipation opioid pain relievers cause in people taking high doses for a long time, such as cancer patients?

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: